Celera Corporation (NASDAQ: CRA) has made the transition away from its old ties and is now its own operating entity. That is also correct with just the tree letter call sign for its news NASDAQ ticker, as those changes have been allowed for some time. As the PR noted, “… a strong financial position, balance sheet and pipeline with no debt. It is a leader in diagnostics and personalized medicine, with genetic discoveries and tests predict risk and optimize therapy for dozens of diseases.”
We should get the full data on its operations, guidance, financials, and possible long-term estimates in the coming weeks now that its quarter ended yesterday. There was some fairly recent data on this, although we have learned that it’s always more trusted data when it has been set rather than when there is pondering over it.
What has been interesting is that this old genomics leader has really been on the road to diversifying away from what many have thought of as science fiction into a company with real tests and a real pipeline. Its partnership with Berkeley Heart Lab will launch a diagnostic test for coronary heart disease this month, which should indicate patient risk and response to statin therapy.
The company’s portfolio includes tests for HIV and clotting test for menopause and women on birth control, and biomarkers for conditions such as oncology through a partnership with Merck.
Jon Ogg
July 1, 2008
